Bicycle Therapeutics (BCYC) Free Cash Flow (2018 - 2026)
Bicycle Therapeutics (BCYC) posted Free Cash Flow of -$66.6 million for Q1 2026, down 234.53% on a QoQ basis from -$19.9 million in Q4 2025, and up 23.38% year-over-year from -$54.0 million in Q1 2025.
Bicycle Therapeutics (BCYC) Free Cash Flow (2018 - 2026) Analysis & Trends
Bicycle Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$66.6 million for Q1 2026.
- Quarterly Free Cash Flow rose 23.38% year-over-year to -$66.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$231.7 million (down 27.27% YoY) and the FY2025 annual result came in at -$252.0 million, down 51.86% from the prior year.
- Free Cash Flow was -$66.6 million for Q1 2026 at Bicycle Therapeutics, down from -$19.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $33.8 million in Q2 2023 and bottomed at -$87.0 million in Q1 2025.
- A 5-year average of -$38.4 million and a median of -$40.3 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow soared 201.47% — and 2024, when it tumbled 2537.0%.
- Bicycle Therapeutics' Free Cash Flow stood at -$31.8 million in 2022, then sank by 49.07% to -$47.3 million in 2023, then soared by 79.37% to -$9.8 million in 2024, then tumbled by 104.01% to -$19.9 million in 2025, then sank by 234.53% to -$66.6 million in 2026.
- Business Quant data shows BCYC's Free Cash Flow at -$66.6 million in Q1 2026, -$19.9 million in Q4 2025, and -$71.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Bicycle Therapeutics | 289.88 Mn | 289.88 Mn | - | -66.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.64 Mn |
| Mar 31, 2026 | -66.64 Mn |
| Dec 31, 2025 | -19.92 Mn |
| Dec 31, 2025 | -19.92 Mn |
| Sep 30, 2025 | -71.85 Mn |
| Sep 30, 2025 | -71.85 Mn |
| Jun 30, 2025 | -73.28 Mn |
| Jun 30, 2025 | -73.28 Mn |
| Mar 31, 2025 | -86.97 Mn |
| Mar 31, 2025 | -86.97 Mn |
| Dec 31, 2024 | -9.76 Mn |
| Dec 31, 2024 | -9.76 Mn |
| Sep 30, 2024 | -40.27 Mn |
| Sep 30, 2024 | -40.27 Mn |
| Jun 30, 2024 | -45.05 Mn |
| Jun 30, 2024 | -45.05 Mn |
| Mar 31, 2024 | -70.88 Mn |
| Mar 31, 2024 | -70.88 Mn |
| Dec 31, 2023 | -47.34 Mn |
| Dec 31, 2023 | -47.34 Mn |